Bowel Disease Clinical Trials

232 recruitingLast updated: June 18, 2026

There are 232 actively recruiting bowel disease clinical trials across 54 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, London, United Kingdom, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Bowel Disease Trials at a Glance

232 actively recruiting trials for bowel disease are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Not Applicable with 64 trials, with the heaviest enrollment activity in New York, London, and Boston. Lead sponsors running bowel disease studies include Massachusetts General Hospital, Changhai Hospital, and McMaster University.

Browse bowel disease trials by phase

Treatments under study

About Bowel Disease Clinical Trials

Looking for clinical trials for Bowel Disease? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bowel Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bowel Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 232 trials

Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Not Applicable

Intestinal Organoids

Crohn DiseaseDigestive System DiseasesInflammatory Bowel Disease, Ulcerative Colitis Type
Rennes University Hospital90 enrolled1 locationNCT05294107
Recruiting

Immune Regulation in Ulcerative Colitis or Crohn s Disease

Ulcerative ColitisInflammatory Bowel DiseaseChrohn's Disease
National Institute of Allergy and Infectious Diseases (NIAID)1,000 enrolled1 locationNCT00001184
Recruiting
Not Applicable

BOOM-IBD2 Pivotal Clinical Trial

Inflammatory Bowel DiseasesUlcerative Colitis
Boomerang Medical137 enrolled19 locationsNCT06571669
Recruiting

Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases

Cytomegalovirus (CMV)Inflammatory Bowel Disease (IBD)
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled1 locationNCT06793124
Recruiting

Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease

IBD (Inflammatory Bowel Disease)Ulcerative Colitis (UC)Crohn Disease (CD)
Shmuel Kivity, MD40 enrolled1 locationNCT07644117
Recruiting

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

Crohn DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag A.G., Switzerland50 enrolled1 locationNCT07532213
Recruiting
Not Applicable

AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis

ColitisUlcerative Colitis (UC)Inflammatory Bowel Disease (IBD)
ENBIOSIS BIOTECHNOLOGIES162 enrolled1 locationNCT07619638
Recruiting
Not Applicable

A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis

Inflammatory Bowel Disease
Rush University Medical Center30 enrolled2 locationsNCT05579392
Recruiting

A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea

Inflammatory Bowel Diseases
Janssen Korea, Ltd., Korea8,000 enrolled1 locationNCT07520747
Recruiting

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag G.m.b.H500 enrolled1 locationNCT07102368
Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag Ltd.220 enrolled1 locationNCT07242248
Recruiting
Phase 2

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

ColitisInflammatory Bowel DiseasesUlcerative Colitis+1 more
Spyre Therapeutics, Inc.645 enrolled223 locationsNCT07012395
Recruiting
Phase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Inflammatory Bowel DiseasesCrohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)385 enrolled226 locationsNCT06226883
Recruiting
Phase 1

A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult

IBD (Inflammatory Bowel Disease)Ulcerative Colitis (UC)CD - Crohn's Disease+2 more
Benethera (Shaoxing) Biotechnology Co., Ltd.68 enrolled1 locationNCT07632573
Recruiting
Phase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative Colitis+1 more
Eli Lilly and Company150 enrolled67 locationsNCT04844606
Recruiting
Phase 1

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

Inflammatory Bowel DiseasesUlcerative ColitisClostridioides Difficile Infection
University of Alberta85 enrolled2 locationsNCT07401680
Recruiting
Not Applicable

Gut Oxygen Therapy for Ischemic-Hypoxic Bowel Disease

Ischemic Bowel DiseaseHypoxic Events
The Second Hospital of Nanjing Medical University90 enrolled1 locationNCT07621367
Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Indeterminate Colitis+1 more
University of North Carolina, Chapel Hill200 enrolled9 locationsNCT07237516
Recruiting

Mechanism of Chronic Pain in Patients With IBD

Inflammatory Bowel Diseases
Queen Mary University of London25,600 enrolled1 locationNCT04995224